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Background. Data on bupivacaine concentrations in the cerebral spinal fluid (CSF) during
spinal anaesthesia are scarce. The purpose of this study was to determine the concentration of
bupivacaine in the lumbar CSF of patients with an adequate level of spinal anaesthesia after
injection of plain bupivacaine 0.5%.
Methods. Sixty patients with an adequate level of spinal block after standardized adminis-
tration of plain bupivacaine 20 mg in men and of 17.5 mg in women were studied. To measure
the CSF bupivacaine concentration, we performed a second lumbar spinal puncture and
obtained a CSF sample at a randomized time point 5–45 min after the bupivacaine injection. In
addition, we calculated the half-life of bupivacaine in the CSF and tested the hypothesis that
the level of spinal block is related to the lumbar CSF bupivacaine concentration.
Results. Men and women had CSF bupivacaine concentrations ranging from 95.4 to 773.0 mg
ml21 (median 242.4 mg ml21) and from 25.9 to 781.0 mg ml21 (median 187.6 mg ml21), respect-
ively. The large variability of bupivacaine concentrations obtained at similar times after subarach-
noid administration made calculation of a meaningful half-life of bupivacaine in CSF impossible.
There was no association between CSF bupivacaine concentration and spinal block level, and CSF
bupivacaine concentrations for the same spinal block level differed between patients by six-fold.
Conclusions. There is a large variability of CSF bupivacaine concentrations in patients with an
adequate level of spinal anaesthesia.
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Spinal anaesthesia is a commonly used regional anaesthe-
sia technique.1 – 3 The skills to perform this technique are
easy to learn, and the success rates are typically high,
ranging from 80% to 90%.4 – 6 Although injection of an
inadequate dose of local anaesthetic into the intrathecal
space, due to technical or dosing errors, is regarded as the
most frequent cause for an insufficient or failed spinal
anaesthesia,7 other reported causes include dural ectasia in
patients with Marfan’s syndrome,8 a very large intrathecal
volume,9 and resistance to bupivacaine.10
Little is known about bupivacaine concentrations in the
cerebrospinal fluid (CSF) necessary to achieve an adequate
level of spinal block and about the CSF kinetics of
bupivacaine in humans. We are aware of only three
studies,11–13 which include a total of 51 patients with
reported bupivacaine concentrations in the CSF during suc-
cessful spinal anaesthesia. There is a large variability in the
reported CSF bupivacaine concentrations. This may be due to
(i) different dosing; (ii) different physical properties of the
bupivacaine solutions used, that is, bupivacaine–HCl vs bupi-
vacaine–CO2 and hyperbaric vs hypobaric solutions; and (iii)
different CSF sampling, i.e. by a second spinal puncture or
by aspiration through a catheter placed in the intrathecal
space. The differences between these studies and the small
†This article is accompanied by Editorial I.
# The Author [2009]. Published by Oxford University Press on behalf of The Board of Directors of the British Journal of Anaesthesia. All rights reserved.
For Permissions, please email: journals.permissions@oxfordjournal.org
British Journal of Anaesthesia 102 (6): 832–8 (2009)
doi:10.1093/bja/aep049 Advance Access publication March 26, 2009
overall number of patients studied might explain the large
variability in the CSF bupivacaine concentrations reported.
The primary aim of this study was to determine the con-
centration of bupivacaine in the lumbar CSF of patients
with an adequate level of spinal anaesthesia after injection
of plain bupivacaine 0.5%. In addition, we calculated the
half-life of bupivacaine in the CSF and tested the hypoth-
esis that the level of spinal block is related to the lumbar
CSF bupivacaine concentration. Finally, we tested the
hypothesis that moving patients after injection of plain
bupivacaine increases the level of sensory block.
Methods
The study protocol was approved by the local ethics com-
mittee of the University Hospital Basel, Basel,
Switzerland, and written informed consent was obtained
from each patient. Inclusion criteria were age between 50
and 75 yr, ASA physical status I or II, body height 150–
185 cm, and a BMI ,30 kg m22. Patients with a history of
post-puncture headache were not eligible for the study.
Exclusion criteria that resulted in abandonment of a second
spinal puncture in the intervention group were spinal block
levels below T11 and a technically difficult initial spinal
puncture at the time of bupivacaine administration.
The 120 study patients were randomly assigned to an
intervention or a control group using a computer-generated
random list. Sixty patients in the intervention group under-
went two spinal punctures: the first puncture was per-
formed for injecting plain bupivacaine 0.5%
(Carbostesinw, Astra Pharmaceutica AG, Dietikon,
Switzerland) and obtaining spinal anaesthesia, the second
for obtaining a 1 ml CSF sample for subsequent analysis
of CSF bupivacaine concentration. The 60 patients in the
control group underwent only one spinal puncture for
injecting plain bupivacaine 0.5%. The control group was
included to study the effect of turning on block level. No
second lateral turning and no second spinal puncture were
performed in the control group, and no CSF sample was
obtained for measurement of bupivacaine concentration.
To study whether men and women require the same
dose of intrathecally administered bupivacaine to achieve
similar lumbar CSF concentrations, we analysed men and
women separately. As all men received bupivacaine 20 mg
and all women bupivacaine 17.5 mg, we calculated the
ratios between the CSF bupivacaine concentration and
body weight, and the ratios between CSF bupivacaine con-
centration, body weight, and dose.
Standard clinical monitoring and peripheral venous
access was established in all patients. All patients were
then placed in the lateral position and a spinal puncture
was performed at the L3/L4 level using a median approach
and a 25 G pencil-point needle (Polymedicw, Temena
SRL, Bondy, France). Men and women were injected with
20 and 17.5 mg of plain bupivacaine 0.5%, respectively.
Before and after bupivacaine injection, free aspiration of
CSF was tested to make sure that the needle opening was
correctly positioned in the intrathecal space. After injec-
tion of the bupivacaine, all patients were placed back in
the supine position, and spinal block level measurements
were performed with cold-warm discrimination using
cotton swabs soaked with ether at 5, 15, 30, and 45 min.
When spinal block levels were asymmetric, the median
level was used for analysis. In the intervention group, a
computer-generated randomization chart was used to
assign a time interval of 5–45 min between intrathecal
bupivacaine administration and aspiration of a 1 ml CSF
sample for analysis of the bupivacaine lumbar CSF con-
centration. For the second spinal puncture, these patients
were again placed in the same lateral position, and the
puncture was performed in the same manner and at the
same level as the first puncture. The CSF samples obtained
were frozen at –208C. The bupivacaine concentration in
the CSF was determined by reversed phase high-
performance liquid chromatography using UV detection
(wavelength 210 nm), which allows for quantification of
concentrations as low as 50 ng ml21. Between-assay and
within-assay variability was below 10% (coefficient of
variation). All determinations were done in duplicate.14
Follow-up for possible post-spinal headache was obtained
by clinical visits on the first, third, and seventh day after
surgery. Post-spinal headache was diagnosed, if the patient
described a headache that was aggravated in the upright
position and diminished in the supine position.
Concentration data are presented as range and median,
and were analysed using the Mann–Whitney U-test.
Maximum cephalad spread between the control and the
intervention groups was analysed using the Mann–
Whitney U-test. GraphPad Prism Version 4 (GraphPad
Software, San Diego, CA, USA) was used for all calcu-
lations. P,0.05 was considered statistically significant.
Results
Patient characteristics are shown in Table 1. At the first
spinal puncture, CSF could be freely aspirated in all
patients both before and after bupivacaine administration.
No patient had a maximum cephalad spread below T11 or
a technically difficult initial spinal puncture; so, no patient
was excluded from the study. The level of spinal block in
the 120 patients was between T11 and T1. CSF samples of
Table 1 Characteristics of 60 control group patients and 54 intervention
group patients. Values are median (range)
Control group
(n560)
Intervention group
(n554)
Men 40 33
Women 20 21
Age (yr) 62 (38–75) 64 (47–75)
Height (cm) 172 (152–190) 170 (155–190)
Weight (kg) 77 (50–99) 73 (50–100)
BMI (kg m22) 26 (21–36) 25 (17–33)
CSF bupivacaine concentrations
833
54 patients (33 men and 21 women) from the intervention
group were available for analysis of bupivacaine concen-
tration; six samples were lost. The exact time of aspiration
of the CSF sample was between 5 and 51 min after
intrathecal administration of bupivacaine.
Men had lumbar CSF bupivacaine concentrations
ranging from 95.4 to 773.0 mg ml21 (median 242.4 mg
ml21) and women 25.9 to 781.0 mg ml21 (median 187.6
mg ml21) (Fig. 1). The ratios between the CSF bupivacaine
concentration and the intrathecally administered bupiva-
caine dose were similar in men and women (Fig. 2A). Also
similar in men and women were the ratios between the
CSF bupivacaine concentration and body weight, and the
ratios between the CSF bupivacaine concentration, body
weight, and dose (Fig. 2B). Using non-linear regression
analysis and assuming a mono-exponential decay, the esti-
mated half-life of bupivacaine in the CSF was 50.8 min
(95% CI 2.4–128.2 min). The goodness of fit (r2) of the
non-linear curve was 0.26 (Fig. 1).
The results show a large range of bupivacaine concen-
trations in the lumbar CSF at every time point measured
(Fig. 1). No relationship was detected between bupiva-
caine concentrations in the CSF and spinal block levels.
CSF bupivacaine levels for the same spinal block level
were similar in men and women (Fig. 3). In both men and
women, the CSF bupivacaine concentrations obtained at
similar time points after bupivacaine administration dif-
fered up to six-fold (Fig. 3).
Forty-four patients from the intervention group that
were repositioned laterally for the second CSF puncture
within 30 min of injection of the bupivacaine had signifi-
cantly more blocked segments after 45 min than the 60
control group patients who were not repositioned (median
18, range 13–22 vs 17, range 11–21; P¼0.015), and as a
consequence had significantly higher spinal block levels
(Fig. 4). Initial left to right side differences in the
extension of the spinal block were observed in eight
patients 5 min after bupivacaine administration but were
undetectable by the time of the 45 min control.
One patient from the control group and no patients from
the intervention group developed a post-spinal headache.
Nine patients (16%) of the intervention group and 10 patients
(16%) of the control group reported a non-specific headache.
Discussion
Our results show that bupivacaine concentrations in the
lumbar CSF of patients with an adequate spinal anaesthetic
block are highly variable (Fig. 1). The variability of
samples obtained at similar times after bupivacaine admin-
istration was up to six-fold. The variability in CSF bupiva-
caine concentrations was similar in men and women
(Figs 1 and 2), as were the measured concentrations with
respect to body weight, height, and dose. This finding is in
agreement with the conclusion of Hocking and
Wildsmith15 that men and women develop a similar cepha-
lad spread of intrathecally administered bupivacaine.
There was no correlation between bupivacaine concen-
trations at corresponding times and the spinal block level
45 min after bupivacaine administration (Fig. 3). For
example, the bupivacaine concentrations were 782 and 186
mg ml21 5 min after bupivacaine administration in two
women whose sensory block levels after 45 min were at
T6 and T4, respectively. This variability was not restricted
to the early period after intrathecal bupivacaine adminis-
tration but persisted throughout the study period. For
example, the bupivacaine concentrations were 335 and 117
mg ml21 45 and 44 min after bupivacaine administration
in two men whose sensory block levels at this time were
at T8 and T6, respectively (Fig. 2A).
The variability in lumbar CSF bupivacaine concen-
trations in our sample correlates well with the findings of
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Fig 1 Kinetics of bupivacaine in CSF during spinal anaesthesia in 54 study patients. Bupivacaine concentration is given in mg ml21.
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previous studies.11 – 13 We had postulated that the largely
differing CSF bupivacaine concentrations in the previous
studies were due to methodological differences in conjunc-
tion with the small sample sizes. The findings of our
larger study show that the variability is also present if the
above-mentioned factors are controlled, suggesting that
individual anatomical factors have a major influence. In
the absence of systematic human studies in this field, we
can only speculate about these potential factors. Possible
factors might be the non-uniform distribution of the local
anaesthetic in the subarachnoid space and the limited utility
in using a single point lumbar sample for drawing con-
clusions regarding the more global movement and intrathe-
cal distribution of bupivacaine. Although there will be a
concentration gradient away from the point of injection, it
will probably not be constant at any particular level, not
even well below the upper level of the block. Both the time
needed for complete mixture of bupivacaine and CSF and
the time that bupivacaine is capable of moving indepen-
dently cannot be defined by our data. However, the obser-
vation of a higher maximum cephalad spread in patients
with a change in body position within 30 min of injection
(but not after that time) suggests that the bupivacaine has
not mixed completely with CSF within 30 min.
Another factor that might have contributed to the large
variability in lumbar CSF bupivacaine concentrations is
the variability of CSF volume in the intrathecal space. A
large variability in the CSF volume in the intrathecal
space was reported by Hogan and colleagues,16 who found
that the volume of lumbosacral CSF varied from 28 to 81
ml in humans. This variability may at least partially
explain a variable dilution and spread of bupivacaine in
the CSF of patients during spinal anaesthesia, and there-
fore, a variable level of neural block. This potential factor
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Fig 2 CSF bupivacaine concentration measured at different time points. (A) Bupivacaine concentration (mg ml21) divided by the intrathecally
administered bupivacaine dose (mg) vs time in 54 study patients. (B) Ratio of CSF bupivacaine concentration (mg ml21) divided by the intrathecally
administered bupivacaine dose (mg) and weight (kg) vs time in 54 study patients.
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is supported by two case reports of failed spinal anaesthe-
sias: one in a healthy young woman who was subsequently
found to have an unusually large intrathecal volume by
magnetic resonance imaging;9 and the second in two par-
turients with Marfan’s syndrome with documented ectatic
thecal sacs.8 A randomized study that found a higher
cephalad spread of the spinal block when 5 ml of CSF
was removed before intrathecal injection of bupivacaine
further supports the importance of CSF volume.17
Unfortunately, the volume of CSF does not correlate with
external physical examination,18 – 20 and thus, cannot be
considered when estimating the dose of local anaesthetic
for spinal anaesthesia in individual patients.
Other factors that might have contributed to the variabil-
ity in lumbar bupivacaine concentrations in our study
patients are non-standardized technical factors during
bupivacaine injection including orientation of the port of
the pencil-point needle and speed of injection, or the use
of barbotage. We did not use barbotage and did not
control the orientation of the needle port and the speed of
bupivacaine injection. However, based on the observation
that a 10-fold difference in speed of subarachnoid bupiva-
caine injection did not affect spread or onset of sensory
and motor block, Stienstra and Van Poorten21 have con-
cluded that the speed of injection does not affect subarach-
noid distribution of plain bupivacaine 0.5%. In summary,
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Fig 3 Spinal block level and lumbar CSF bupivacaine concentration in women and men determined at the time of the second spinal tap.
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Fig 4 Effect of change in body position within and after the first 30 min after intrathecal bupivacaine administration on spinal block level in 44
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the reasons for the large variability in lumbar bupivacaine
concentrations in our study patients remain unclear. It is
interesting to note that all study patients had an adequate
spinal block, independent of the presence of very low (or
high) lumbar CSF bupivacaine concentrations.
We attempted to calculate the estimated half-life of
intrathecal bupivacaine using our data, but the described
large range of bupivacaine concentrations (Fig. 2A)
resulted in a very low goodness of fit (r2¼0.26), indicating
that the calculated value is not clinically meaningful.
An analysis of maximum cephalad spread after 45 min
revealed that patients who had an additional position
change within 30 min of injection had a significantly
higher spinal block level than those remaining in the
supine position (Fig. 4). This finding may be explained by
the fact that spread of spinal anaesthesia is most dynamic
during the first 30 min after administration.15 22 Our find-
ings are in agreement with those of Russell23 who found
an increase of two to three segments in the block level,
when patients were turned from a lateral to the supine pos-
ition, and from the supine to prone positions within 35
min of plain bupivacaine 0.5% administration. An effect
of CSF aspiration on block extension in our patients with
an additional position change cannot be ruled out, but the
small amount of CSF withdrawn (1 ml) questions the rel-
evance of this aspiration.
One limitation of our study is that only one bupivacaine
concentration was available from each patient of the inter-
vention group. Therefore, the description of the kinetics of
bupivacaine in the CSF is based on the assumption that the
medically healthy study patients had a similar clearance of
intrathecal bupivacaine. Deciding on the timing of the CSF
sampling was a difficult issue with no definitively ‘correct’
answer. We had decided to obtain samples at randomized
intervals after the initial bupivacaine injection, but the
large variability in lumbar CSF concentrations in our
patients raises the question if choosing a constant time
interval would have been a more useful study design.
Another limitation is that the initial bupivacaine concen-
tration in the CSF immediately after injection was
unknown. This made it more difficult to find reasonable fits
of the non-linear regression curve. Introducing a catheter
into the intrathecal space would have allowed for repeated
sampling but might have introduced other problems such
as placement of the tip in a small compartment in the
intrathecal space.14 Another limitation is that we adminis-
tered different doses of bupivacaine to men and women.
Although differences in height and in density of the CSF24
between men and women might influence drug require-
ment, there are few data to support the belief that men gen-
erally develop less cephalad spread than women.15 A final
limitation of the study is that the speed of bupivacaine
injection into the intrathecal space and the orientation of
the port during the injection were not standardized.
In summary, we found that lumbar bupivacaine concen-
trations in the CSF of patients with an adequate spinal
anaesthetic block are highly variable, and that there is no
correlation between bupivacaine concentrations at corre-
sponding times and the spinal block level 45 min after
bupivacaine administration. The large variability of bupi-
vacaine concentrations obtained at similar times after sub-
arachnoid administration made calculation of a meaningful
half-life of bupivacaine in CSF impossible. The ratios
between the CSF bupivacaine concentration and the
intrathecally administered bupivacaine dose were similar
in men and women, as were CSF bupivacaine concen-
trations for the same spinal block level. This finding sup-
ports the use of the same dose of intrathecally
administered bupivacaine in men and women to achieve
similar lumbar CSF concentrations. Finally, we found that
a position change within 30 min after spinal anaesthesia
increases the spinal block level after administration of
plain bupivacaine 0.5%.
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